nCOVID -19 pandemic outbreak in India - A concise review
Abstract
The beginning of 2021 has seen outbreaks of novel coronavirus COVID-19 infections, which have become a global pandemic. It is considered to have higher contagiousness and mortality compared to SARS and MERS. Clinical manifestations of nCOVID-19 symptoms are identified as coughs, fevers, vomiting, chills, joint pain, shortness of breath, and diarrhea. Older people over 70 years of age and those with chronic debilitating diseases such as end-stage illness, diabetes mellitus, hypertension, and pulmonary diseases are at a higher risk of mortality from nCOVID-19 infection. Currently, no specific approved antiviral drugs are available against nCOVID-19. Considering this imminent need, scientists and physicians have been racing to better understand this new pandemic virus-specific mechanism; pathophysiology, and target site of the disease to find effective therapeutic agents and vaccines. This review summarised the origin, transmission, clinical symptoms, and conventional outcome treatment strategies of infection. It also included a discussion of the potential for recurrence. In our study, we emphasised reported potential repurposing drugs that are effective against SARS, MERS, and nCOVID-19, among other diseases. Our early knowledge will provide an overview of the intelligence basis work for currently existing therapeutic vaccines against nCOVID-19 that will be useful in the development of future vaccines.
Downloads
References
Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7
Guan Y, Zheng BJ, He YQ, et al. Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China. Science. 2003;302(5643):276-278. doi:10.1126/science.1087139
Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerging Infectious Diseases. 2005;11(12):1860-1865. doi:10.3201/eid1112.041293
Haagmans BL, van den Brand JMA, Provacia LB, et al. Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. Journal of Virology. 2015;89(11):6131-6135. doi:10.1128/JVI.00661-15
Memish ZA, Al-Tawfiq JA, Makhdoom HQ, et al. Respiratory Tract Samples, Viral Load, and Genome Fraction Yield in Patients With Middle East Respiratory Syndrome. J Infect Dis. 2014;210(10):1590-1594. doi:10.1093/infdis/jiu292
Zhou P, Yang X-L, Wang X-G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. Published online January 23, 2020:2020.01.22.914952. doi:10.1101/2020.01.22.914952
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-269. doi:10.1038/s41586-020-2008-3
de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology. 2016;14(8):523-534. doi:10.1038/nrmicro.2016.81
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565-574. doi:10.1016/S0140-6736(20)30251-8
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology. 2019;17(3):181-192. doi:10.1038/s41579-018-0118-9
Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. Coronaviruses. 2015;1282:1-23. doi:10.1007/978-1-4939-2438-7_1
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052
Barlan A, Zhao J, Sarkar MK, et al. Receptor Variation and Susceptibility to Middle East Respiratory Syndrome Coronavirus Infection. Journal of Virology. 2014;88(9):4953-4961. doi:10.1128/JVI.00161-14
Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC medicine. 2015;13:210. doi:10.1186/s12916-015-0450-0
Kang CK, Song K-H, Choe PG, et al. Clinical and Epidemiologic Characteristics of Spreaders of Middle East Respiratory Syndrome Coronavirus during the 2015 Outbreak in Korea. J Korean Med Sci. 2017;32(5):744-749. doi:10.3346/jkms.2017.32.5.744
Drosten C, Günther S, Preiser W, et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine. 2003;348(20):1967-1976. doi:10.1056/NEJMoa030747
SARS Virus: The Beginning of the Unraveling of a New Coronavirus - Abstract - Journal of Biomedical Science 2003, Vol. 10, No. 6 - Karger Publishers. Accessed October 10, 2020. https://www.karger.com/Article/Abstract/74077
Ng DL, Al Hosani F, Keating MK, et al. Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. The American Journal of Pathology. 2016;186(3):652-658. doi:10.1016/j.ajpath.2015.10.024
World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. Pediatr Med Rodz. 2020;16(1):9-26. doi:10.15557/PiMR.2020.0003
Arabi YM, Harthi A, Hussein J, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection. 2015;43(4):495-501. doi:10.1007/s15010-015-0720-y
Peiris J, Lai S, Poon L, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-1325. doi:10.1016/S0140-6736(03)13077-2
Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet (London, England). 2003;361(9371):1767-1772. doi:10.1016/s0140-6736(03)13412-5
Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious Diseases. 2013;13(9):752-761. doi:10.1016/S1473-3099(13)70204-4
Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2014;29:301-306. doi:10.1016/j.ijid.2014.09.003
Lee N, Hui D, Wu A, et al. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. New England Journal of Medicine. 2003;348(20):1986-1994. doi:10.1056/NEJMoa030685
Al-Hameed F, Wahla AS, Siddiqui S, et al. Characteristics and Outcomes of Middle East Respiratory Syndrome Coronavirus Patients Admitted to an Intensive Care Unit in Jeddah, Saudi Arabia. Journal of Intensive Care Medicine. 2016;31(5):344-348. doi:10.1177/0885066615579858
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. European Review. Published February 27, 2020. Accessed October 10, 2020. https://www.europeanreview.org/article/20379
Organization WH. Surveillance for human infection with Middle East respiratory syndrome coronavirus (MERS-CoV): interim guidance. Published online 2018. Accessed October 10, 2020. https://apps.who.int/iris/handle/10665/177869
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls. StatPearls Publishing; 2020. Accessed October 10, 2020. http://www.ncbi.nlm.nih.gov/books/NBK554776/
Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL. MERS: emergence of a novel human coronavirus. Curr Opin Virol. 2014;5:58-62. doi:10.1016/j.coviro.2014.01.010
Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;30(6):3306-3309. doi:10.1007/s00330-020-06731-x
Memish ZA, Perlman S, Kerkhove MDV, Zumla A. Middle East respiratory syndrome. The Lancet. 2020;395(10229):1063-1077. doi:10.1016/S0140-6736(19)33221-0
Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Medical Research. 2020;7(1):4. doi:10.1186/s40779-020-0233-6
Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P. Treatment and vaccines for severe acute respiratory syndrome. The Lancet Infectious Diseases. 2005;5(3):147-155. doi:10.1016/S1473-3099(05)01307-1
Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nature Reviews Microbiology. 2013;11(12):836-848. doi:10.1038/nrmicro3143
Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Scientific Reports. 2017;7:43395. doi:10.1038/srep43395
Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. New England Journal of Medicine. 2020;382(10):929-936. doi:10.1056/NEJMoa2001191
Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924
Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. The New England Journal of Medicine. 2003;348(20):1995-2005. doi:10.1056/NEJMoa030634
Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. The New England Journal of Medicine. 2003;348(20):1977-1985. doi:10.1056/NEJMoa030666
Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26:2040206618764483. doi:10.1177/2040206618764483
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nature Medicine. 2013;19(10):1313-1317. doi:10.1038/nm.3362
Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571-577. doi:10.1099/vir.0.061911-0
Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review. Journal of Infection and Public Health. 2018;11(1):9-17. doi:10.1016/j.jiph.2017.08.009
Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep. 2013;3. doi:10.1038/srep01686
Wong CK, Lam CWK, Wu AKL, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical and Experimental Immunology. 2004;136(1):95-103. doi:10.1111/j.1365-2249.2004.02415.x
Savarino A, Trani LD, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. The Lancet Infectious Diseases. 2006;6(2):67-69. doi:10.1016/S1473-3099(06)70361-9
Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Research. 2013;23(2):300-302. doi:10.1038/cr.2012.165
Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery. 2020;19(3):149-150. doi:10.1038/d41573-020-00016-0
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. Journal of Medical Virology. 2020;92(4):441-447. doi:10.1002/jmv.25689
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of Infectious Diseases. 2015;211(1):80-90. doi:10.1093/infdis/jiu396
Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. The Cochrane Database of Systematic Reviews. 2019;2:CD010406. doi:10.1002/14651858.CD010406.pub3
Koenig KL. Identify-Isolate-Inform: A Modified Tool for Initial Detection and Management of Middle East Respiratory Syndrome Patients in the Emergency Department. West J Emerg Med. 2015;16(5):619-624. doi:10.5811/westjem.2015.7.27915
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. Journal of Medical Virology. 2020;92(5):479-490. doi:10.1002/jmv.25707
Chan JFW, Chan K-H, Kao RYT, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. The Journal of Infection. 2013;67(6):606-616. doi:10.1016/j.jinf.2013.09.029
Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256. doi:10.1136/thorax.2003.012658
Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antiviral Therapy. 2016;21(5):455-459. doi:10.3851/IMP3002
de Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. The Journal of General Virology. 2013;94(Pt 8):1749-1760. doi:10.1099/vir.0.052910-0
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. European Review. Published July 27, 2018. Accessed October 10, 2020. https://www.europeanreview.org/article/15635
Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Global seasonal occurrence of middle east respiratory syndrome coronavirus (MERS-CoV) infection. European Review for Medical and Pharmacological Sciences. 2018;22(12):3913-3918. doi:10.26355/eurrev_201806_15276
Ko A, Ah H, M AB, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection - clinicopathological and ultrastructural study. Histopathology. 2017;72(3):516-524. doi:10.1111/his.13379
Lee JY, Kim Y-J, Chung EH, et al. The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015. BMC Infectious Diseases. 2017;17(1):498. doi:10.1186/s12879-017-2576-5
Times TNY. Covid World Map: Tracking the Global Outbreak. The New York Times. https://www.nytimes.com/interactive/2020/world/coronavirus-maps.html. Accessed October 10, 2020.
Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227-231. doi:10.1038/nature12328
Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Eurosurveillance. 2012;17(39):20285. doi:10.2807/ese.17.39.20285-en
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269-271. doi:10.1038/s41422-020-0282-0
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications. 2020;11(1):222. doi:10.1038/s41467-019-13940-6
Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. The Journal of Antimicrobial Chemotherapy. 2004;53(1):4-9. doi:10.1093/jac/dkh029
Guo D. Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases. Virol Sin. Published online February 11, 2020:1-3. doi:10.1007/s12250-020-00204-7
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Chembiochem: A European Journal of Chemical Biology. 2020;21(5):730-738. doi:10.1002/cbic.202000047
Maxmen A. More than 80 clinical trials launch to test coronavirus treatments. Nature. 2020;578(7795):347-348. doi:10.1038/d41586-020-00444-3
Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402-405. doi:10.1038/nature13027
Beigelman A, Mikols RL, Gunsten SP, Cannon CL, Brody SL, Walter MJ. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respiratory Research.:2010.
Kanoh S, Rubin BK. Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications. Clinical Microbiology Reviews. 2010;23(3):590-615. doi:10.1128/CMR.00078-09
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(20):10970-10975. doi:10.1073/pnas.2005615117
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
